Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

(2020) Chloe Orkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

1329. Experiences and Emotional Challenges of Antiretroviral Treatment (ART)—Findings from the Positive Perspectives Study

(2019) Patricia De Los Rios et al.   Open Forum Infectious Diseases

1532. Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1-Infected Subjects

(2019) Kelong Han et al.   Open Forum Infectious Diseases

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis

(2016) Zara Shubber et al.   PLOS MEDICINE

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy

(2014) Kasey R. Claborn et al.   Psychology Health & Medicine

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION